In part 3 of 3 on Navigating KOL Engagement Dynamics-KOL Categories by Phase, we present our third key insight from our KOL engagement strategy report. This article outlines categories of Thought Leader pharmaceutical companies engage during each phase of a product development lifecycle. Dominance of Specialists and Academics Across all studied regions, companies overwhelmingly prioritize [...]
In part 2 of 3 on Navigating KOL Engagement Dynamics-Activities by Phase, we present our second key insight from our KOL engagement strategy report. This article addresses the type of activity pharmaceutical companies seek from KOLs who possess specific experiences suited to support the activities of the pharmaceutical organization during particular times within a product [...]
In part 1 of 3 on Navigating KOL Engagement Dynamics-Influence Levels by Phase, we present our first key insight from our KOL engagement strategy report. This article addresses how pharmaceutical companies engage with KOLs possessing specific backgrounds suited to support the activities of the pharmaceutical organization during particular times within a product development lifecycle. The [...]
Often lost in the MSL training modules is the importance of mastering first impressions and ensuring this "art" is part of the Medical Science Liaison skills set. Did you know? Research indicates that most individuals form their initial impression of someone within a mere seven seconds.* Moreover, consider this: A recent study on website visitors [...]
We recently conducted research on how the pandemic has transformed the way Medical Science Liaisons interact with Thought Leaders, and findings show a fundamental shift in MSL-KOL interactions. In pre-pandemic times, the favored means of interaction by both MSLs and KOLs were the traditional in-person face-to-face meeting, followed by email, phone, and virtual platforms (remember [...]
Learning about KOL meeting preferred frequency with Medical Science Liaisons, that is when Thought Leaders can or want to meet MSLs, is an important component of building trust in the MSL-KOL relationships. Since most of the organizations’ field teams coordinate and set the pace for these interactions, it becomes increasingly important to understand what Thought [...]
A successful Medical Affairs launch strategy requires every part of an organization to work in sync. For Medical Affairs, it means that by the time a product “hits” the market, most of the function will be staffed. It also means the medical field team programs will have gradually matured into a fully operational structure. Thought [...]
The Altered Pharmaceutical Thought Leader Pool: How the Implementation of the Sunshine Act and CMS Open Payment Program Changed the KOL Landscape Since the adoption of the Sunshine Act in 2010 and the subsequent thought leaders’ payments reporting on the CMS Open Payment Program in 2014, many things have changed for pharmaceutical companies. It took [...]
Recent research shows KOL lifecycle involvement. There are a significant number of surveyed organizations – 39%, as shown in the figure below – reported that initial engagements with thought leaders start during phase 3 of a product’s lifecycle. Two percent begin at launch, but starting to cultivate thought leader relationships so late in a product [...]
Research shows what European KOLs think of MSLs they interact with. Through the deployment of scientific field teams (MSLs), organizations’ intentions are to share medical and clinical knowledge of products with the thought leaders who in turn can spread the information to physician communities and ultimately enhance patient experiences. In the process, thought leaders become [...]
